PremiumThe FlyKinnate Biopharma sells exarafenib to Pierre Fabre Laboratories Kinnate Biopharma price target raised to $2.59 from $1.50 at Stifel Kinnate Biopharma downgraded to Market Perform from Outperform at William Blair PremiumThe FlyPyxis Oncology announces appointment of Kobayashi as CMO Kinnate Biopharma reports Q3 EPS (65c), consensus (67c) Dell upgraded, Starbucks downgraded: Wall Street’s top analyst calls PremiumThe FlyKinnate Biopharma trading resumes Kinnate Biopharma to reduce workforce by 70%, announces reprioritization plan Kinnate Biopharma trading halted, news pending 
